Current management of prolactinomas

Abstract

Prolactinomas constitute the largest group of pituitary adenomas in autopsy series. However, their relative incidence in recent surgical series is much less impressive since medical treatment with dopamine agonists is routinely employed, which in many cases leads to tumor shrinkage and normalization of prolactin levels. The clinical symptoms of hyperprolactinemia are menstrual dysfunction and galactorrhea in women and loss of libido and potency in men. Prolactinomas may present also as space occupying sellar mass lesions impinging on the adjacent structures like the pituitary gland, cavernous sinus and optic nerves. The standard primary treatment is medical by dopamine agonists. Prolactinomas are the prototype of tumors, the growth of which can be reliably and safely inhibited by specific drugs other than cytostatic chemotherapy. These unfortunately have side effects, like orthostatic hypotension, nausea and vomiting. The effects induced by dopamine agonists are suppressive but not tumoricidal. Thus, the therapeutic effect is only maintained as long as the drug is administered. Consequently, in most cases, treatment has to be continued life-long with a few exceptions, in whom normoprolactinemia persists even after discontinuation of dopamine agonists. Main indications of surgery in prolactinomas are intolerance of the medication, and tumors not responding to dopamine agonists. Occasionally, these may ultimately require radiation therapy. nobreak Remission rates in large series of surgically treated prolactinomas vary between 54% and 86%. In our consecutive series of 540 surgically treated prolactinomas, the normalization rate after transsphenoidal surgery basically depended on the preoperative prolactin levels, tumor size and extension. The remission rate of 82% in microprolactinomas with initial prolactin levels < 200ng/ml would even in small adenomas make one consider surgical treatment as an interesting alternative to long-term medical treatment.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Burrow GN, Wortzman G, Rewcastle NB, Holgate RC, Kovacs K: Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series. N Engl J Med 304: 156–158, 1981

    Google Scholar 

  2. 2.

    Riedel M, Noldus J, Saeger W, Ludecke DK: Sellar lesions associated with isolated hyperprolactinaemia. Morphological, immunocytochemical, hormonal and clinical results. Acta Endocrinol (Copenh.) 113: 196–203, 1986

    Google Scholar 

  3. 3.

    Hardy J: Transsphenoidal surgery of hypersecreting pituitary tumors. In: Kohler PO, Ross GT (eds) Diagnosis and Treatment of Pituitary Tumors. Excerpta Media, Amsterdam, 1972, pp 179–194

    Google Scholar 

  4. 4.

    Besser GM, Parke L, Edwards CRW, Forsythe IA, MacNeilly AS: Galactorrhea; successful treatment with reduction of plasma prolactin levels by bromocriptine. Br Med J 2: 669–672, 1972

    Google Scholar 

  5. 5.

    Nillius SJ, Bergh T, Larsson SG: Pituitary tumors and pregnancy. In: Derome P, Jedynak CP, Peillon F (eds) Second European Workshop on Pituitary Adenomas. Asclepios France, Paris, 1980, pp 103–112

    Google Scholar 

  6. 6.

    Veldhuis JD, Johnson ML: Operating characteristics of the hypothalamo-pituitary-gonadal axis in men: circadian, ultradian, and pulsatile release of prolactin and its temporal coupling with luteinizing hormone. J Clin Endocrinol Metab 67: 116–123, 1988

    Google Scholar 

  7. 7.

    Thorner MO, Vance ML, Horvath E, Kovacs K: The anterior pituitary. In: Wilson JD, Foster DW (eds) Williams Textbook of Endocrinology. WB Saunders, Philadelphia, 1992, pp 221–311

    Google Scholar 

  8. 8.

    Lechan RM: Neuroendocrinology of pituitary hormone regulation. Endocrinol Metab Clin North Am 16: 475–501, 1987

    Google Scholar 

  9. 9.

    Nikolics K, Mason AJ, Szonyi E, Ramachandran J, Seeburg PH: A prolactin-inhibiting factor within the precursor for human gonadotropin-releasing hormone. Nature 316: 511–517, 1985

    Google Scholar 

  10. 10.

    O'Brien T, O'Riordan DS, Gharib H, Scheithauer BW, Ebersold MJ, van Heerden JA: Results of treatment of pituitary disease in multiple endocrine neoplasia, type I. Neurosurgery 39: 273–278, 1996

    Google Scholar 

  11. 11.

    Thapar K, Kovacs K, Laws ER: The classification and molecular biology of pituitary adenomas. Adv Tech Stand Neurosurg 22: 4–53, 1995

    Google Scholar 

  12. 12.

    Herman V, Fagin J, Gonsky R, Kovacs K, Melmed S: Clonal origin of pituitary adenomas. J Clin Endocrinol Metab 71: 1427–1433, 1990

    Google Scholar 

  13. 13.

    Bystrom C, Larsson C, Blomberg C, Sandelin K, Falkmer U, Skogseid B, Oberg K, Werner S, Nordenskjold M: Localization of the MEN1 gene to a small region within chromosome 11q13 by deletion mapping in tumors. Proc Natl Acad Sci USA 87: 1968–1972, 1990

    Google Scholar 

  14. 14.

    Heitz PU, Kloppel G, Polak JM, Staub JJ: Ectopic hormone production by endocrine tumors: localization of hormones at the cellular level by immunocytochemistry. Cancer 48: 2029–2037, 1981

    Google Scholar 

  15. 15.

    Park SK, Keanan MW, Selmanoff M: Graded hyperprolactinemia first suppresses LH pulse frequency and then pulse amplitude in castrated rats. Neuroendocrinology 58: 448–453, 1993

    Google Scholar 

  16. 16.

    Polson DW, Sagle M, Mason HD, Adams J, Jacobs HS, Franks S: Ovulation and normal luteal function during LHRHtreatment ofwomen with hyperprolactinaemic amenorrhoea. Clin Endocrinol (Oxf) 24: 531–537, 1986

    Google Scholar 

  17. 17.

    Klibanski A, Biller BM, Rosenthal DI, Schoenfeld DA, Saxe V: Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J Clin Endocrinol Metab 67: 124–130, 1988

    Google Scholar 

  18. 18.

    Onoda N, Kamezu Y, Takagi S, Shinohara Y, Osamura RY: An autopsy case of invasive pituitary adenoma (prolactinoma) with rapid fatal clinical course due to streptococcal meningitis. Acta Pathol Jpn 42: 832–836, 1992

    Google Scholar 

  19. 19.

    Molitch ME: Diagnosis and treatment of prolactinomas. Adv Intern Med 44: 117–153, 1999

    Google Scholar 

  20. 20.

    De Marinis L, Mancini A, Maira G, Anile C, Menini E, Barbarino A: Postoperative evaluation of dopaminergic tone in prolactinoma patients. II. Plasma thyrotropin response to metoclopramide. J Clin Endocrinol Metab 58: 405–409, 1984

    Google Scholar 

  21. 21.

    Persani L, Beck-Peccoz P, Medri G, Conti A, Faglia G: Thyrotropin alpha-and beta-subunit responses to thyrotropin-releasing hormone and domperidone in normal subjects and in patients with microprolactinomas. Neuroendocrinology 53: 411–415, 1991

    Google Scholar 

  22. 22.

    Scanlon MF, Peters JR, Salvador J, Richards SH, John R, Howell S, Williams ED, Thomas JP, Hall R: The preoperative and postoperative investigation of TSH and prolactin release in the management of patients with hyperprolactinaemia due to prolactinomas and nonfunctional pituitary tumours: relationship to adenoma size at surgery. Clin Endocrinol (Oxf) 24: 435–446, 1986

    Google Scholar 

  23. 23.

    Knosp E, Steiner E, Kitz K, Matula C: Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33: 610–617, 1993

    Google Scholar 

  24. 24.

    Buchfelder M, Fahlbusch R, Nomikos P, et al.: Recent advances in CT and MRI in the diagnosis and followup of hypothalamo-pituitary disease. In: von Werder K, Fahlbusch R (eds) Pituitary Adenomas. Excerpta Medica Elsevier, Amsterdam, 1996, pp 132–145

    Google Scholar 

  25. 25.

    March CM, Kletzky OA, Davajan V, Teal J, Weiss M, Apuzzo ML, Marrs RP, Mishell DR: Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas. Am J Obstet Gynecol 139: 835–844, 1981

    Google Scholar 

  26. 26.

    Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A: The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 68: 412–418, 1989

    Google Scholar 

  27. 27.

    Weiss MH, Teal J, Gott P, Wycoff R, Yardley R, Apuzzo MLJ, Giannota SL, Kletzky O, March C: Natural history of microprolactinomas: six-year follow-up. Neurosurgery 12: 180–183, 1983

    Google Scholar 

  28. 28.

    DelPozo E, Del Re RB, Varga L, Friesen H: The inhibition of prolactin secretion in man by CB-154 (2-Br-alphaergocryptine). J Clin Endocrinol Metab 35: 768–771, 1972

    Google Scholar 

  29. 29.

    Spark RF, Baker R, Bienfang DC, Bergland R: Bromocriptine reduces pituitary tumor size and hypersection. Requiem for pituitary surgery? JAMA 247: 311–316, 1982

    Google Scholar 

  30. 30.

    De Cecco L, Foglia G, Ragni N, Rossato P, Venturini PL: The effect of lisuride hydrogen maleate in the hyperprolactinaemia-amenorrhoea syndrome: clinical and hormonal responses. Clin Endocrinol (Oxf) 9: 491–498, 1978

    Google Scholar 

  31. 31.

    Franks S, Horrocks PM, Lynch SS, Butt WR, London DR: Treatment of hyperprolactinaemia with pergolide mesylate: acute effects and preliminary evaluation of long-term treatment. Lancet 2: 659–661, 1981

    Google Scholar 

  32. 32.

    Dallabonzana D, Liuzzi A, Oppizzi G, Cozzi R, Verde G, Chiodini P, Rainer E, Dorow R, Horowski R: Chronic treatment of pathological hyperprolactinemia and acromegaly with the new ergot derivative terguride. J Clin Endocrinol Metab 63: 1002–1007, 1986

    Google Scholar 

  33. 33.

    Dall'Ara A, Lima L, Cocchi D, Di Salle E, Cancio E, Devesa J, Muller EE: Inhibitory effect of cabergoline on the development of estrogen-induced prolactin-secreting adenomas of the pituitary. Eur J Pharmacol 151: 97–102, 1988

    Google Scholar 

  34. 34.

    Ferrari C, Barbieri C, Caldara R, Mucci M, Codecasa F, Paracchi A, Romano C, Boghen M, Dubini A: Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. J Clin Endocrinol Metab 63: 941–945, 1986

    Google Scholar 

  35. 35.

    Vance ML, Cragun JR, Reimnitz C, Chang RJ, Rashef E, Blackwell RE, Miller MM, Molitch ME: CV 205-502 treatment of hyperprolactinemia. J Clin Endocrinol Metab 68: 336–339, 1989

    Google Scholar 

  36. 36.

    Rasmussen C, Bergh T, Wide L, Brownell J: CV 205-502: a new long-acting drug for inhibition of prolactin hypersecretion. Clin Endocrinol (Oxf) 26: 321–326, 1987

    Google Scholar 

  37. 37.

    Maurer RA: Dopaminergic inhibition of prolactin synthesis and prolactin messenger RNA accumulation in cultured pituitary cells. J Biol Chem 255: 8092–8097, 1980

    Google Scholar 

  38. 38.

    Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R, Joplin G, Robbins RJ, Tyson J, Thorner MO: Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 60: 698–705, 1985

    Google Scholar 

  39. 39.

    Tindall GT, Kovacs K, Horvath E, Thorner MO: Human prolactin-producing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural, and morphometric study. J Clin Endocrinol Metab 55: 1178–1183, 1982

    Google Scholar 

  40. 40.

    Landolt AM, Osterwalder V: Perivascular fibrosis in prolactinomas: is it increased by bromocriptine? J Clin Endocrinol Metab 58: 1179–1183, 1984

    Google Scholar 

  41. 41.

    Bevan JS, Adams CB, Burke CW, Morton KE, Molyneux AJ, Moore RA, Esiri MM: Factors in the outcome of transsphenoidal surgery for prolactinoma and non-functioning pituitary tumour, including pre-operative bromocriptine therapy. Clin Endocrinol (Oxf) 26: 541–556, 1987

    Google Scholar 

  42. 42.

    Landolt AM, Keller PJ, Froesch ER, Mueller J: Bromocriptine: Does it jeopardise the result of later surgery for prolactinomas? Lancet 2: 657–658, 1982

    Google Scholar 

  43. 43.

    Vance ML, Thorner MO: Prolactinomas. Endocrinol Metab Clin North Am 16: 731–753, 1987

    Google Scholar 

  44. 44.

    Molitch ME: Pathologic hyperprolactinemia. Endocrinol Metab Clin North Am 21: 877–901, 1992

    Google Scholar 

  45. 45.

    Bevan JS, Webster J, Burke CW, Scanlon MF: Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 13: 220–240, 1992

    Google Scholar 

  46. 46.

    Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P, Enjalbert A: Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 69: 500–509, 1989

    Google Scholar 

  47. 47.

    Klijn JG, Lamberts SW, Birkenhager JC: TRH test for prolactinoma. Lancet 2: 581–582, 1979

    Google Scholar 

  48. 48.

    Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G: Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 85(6): 2247–2252; 85: 2247-2252, 2000

    Google Scholar 

  49. 49.

    Nomikos P, Fahlbusch R, Buchfelder M: Macroprolactinomas: Persistent normoprolactinemia and disappearence of tumour on MR images after short-term medical treatment with dopamine agonists. Exp Clin Endocrinol Diabetes 108: 193–2000

  50. 50.

    Hildebrandt G, Zierski J, Christophis P, Laun A, Schatz H, Lancranjan I, Klug N: Rhinorrhea following dopamine agonist therapy of invasive macroprolactinoma. Acta Neurochir (Wien) 96: 107–113, 1989

    Google Scholar 

  51. 51.

    Holness RO, Shlossberg AH, Heffernan LP: Cerebrospinal fluid rhinorrhea caused by bromocriptine therapy of prolactinoma. Neurology 34: 111–113, 1984

    Google Scholar 

  52. 52.

    Webster J: Cabergoline and quinagolide therapy for prolactinomas. Clin Endocrinol (Oxf) 53(5): 549–550; 53: 549-550, 2000

    Google Scholar 

  53. 53.

    Landolt AM: Prolactinomas: preoperative bromocriptine treatment. Surgical results. In: Barrow DL (eds) Perspectives in Neurological Surgery. Quality Medical Publishing, St. Louis, 1990, pp 105–115

    Google Scholar 

  54. 54.

    Fahlbusch R, Buchfelder M: Surgical complications. In: Landolt AM, Vance ML, Reilly PL (eds) Pituitary Adenomas. Churchill Livingstone, NewYork, 1996, pp 395–408

    Google Scholar 

  55. 55.

    Laws ER, Kern EB: Complications of trans-sphenoidal surgery. Clin Neurosurg 23: 401–416, 1976

    Google Scholar 

  56. 56.

    Zervas NT: Surgical results for pituitary adenomas: Results of an international survey. In: Black PM, Zervas NT, Ridgway EC, Martin JB (eds) Secretor Tumors of the Pituitary Gland. Raven Press, New York, 1984, pp 377–385

    Google Scholar 

  57. 57.

    Faria MA, Tindall GT: Transsphenoidal microsurgery for prolactin-secreting pituitary adenomas. J Neurosurg 56: 33–43, 1982

    Google Scholar 

  58. 58.

    Domingue JN, Richmond IL, Wilson CB: Results of surgery in 114 patients with prolactin-secreting pituitary adenomas. Am J Obstet Gynecol 137: 102–108, 1980

    Google Scholar 

  59. 59.

    Aubourg PR, Derome PJ, Peillon F, Jedynak CP, Visot A, Le Gentil P, Balagura S, Guiot G: Endocrine outcome after transsphenoidal adenomectomy for prolactinoma: prolactin levels and tumor size as predicting factors. Surg Neurol 14: 141–143, 1980

    Google Scholar 

  60. 60.

    Hardy J, Beauregard H, Robert F: Prolactin-secreting pituitary adenomas: transsphenoidal microsurgical treatment. In: Robyn C, Harter M (eds) Progress in Prolactin Physiology and Pathology. Elsevier/North-Holland Biomedical Press, Amsterdam, 1978, pp 361–370

    Google Scholar 

  61. 61.

    Ahmadi J, North CM, Segall HD, Zee CS, Weiss MH: Cavernous sinus invasion by pituitary adenomas. AJR Am J Roentgenol 146: 257–262, 1986

    Google Scholar 

  62. 62.

    Buchfelder M, Fahlbusch R, Adams EF, Kiesewetter F, Thierauf P: Proliferation parameters for pituitary adenomas. Acta Neurochir Suppl (Wien) 65: 18–21, 1996

    Google Scholar 

  63. 63.

    Barrow DL, Mizuno J, Tindall GT: Management of prolactinomas associated with very high serum prolactin levels. J Neurosurg 68: 554–558, 1988

    Google Scholar 

  64. 64.

    Faglia G, Moriondo P, Travaglini P, Giovanelli MA: Influence of previous bromocriptine therapy on surgery for microprolactinoma. Lancet 1: 133–134, 1983

    Google Scholar 

  65. 65.

    Perrin G, Treluyer C, Trouillas J, Sassolas G, Goutelle A: Surgical outcome and pathological effects of bromocriptine preoperative treatment in prolactinomas. Pathol Res Pract 187: 587–592, 1991

    Google Scholar 

  66. 66.

    Fahlbusch R, Buchfelder M, Schrell U: Short-term preoperative treatment of macroprolactinomas by dopamine agonists. J Neurosurg 807–815, 1987

  67. 67.

    Fahlbusch R, Giovanelli M, Crosignani P, Faglia G, Rjosk HK, von Werder K: Differentiated therapy of microprolactinomas: Significance of transsphenoidal adenomectomy. In: Faglia G, Giovanelli M, McLeod R (eds) Pituitary Microadenomas. Academic Press, London, 1980, pp 443–457

    Google Scholar 

  68. 68.

    Tucker HS, Grubb SR, Wigand JP, Taylon A, Lankford HV, Blackard WG, Becker DP: Galactorrhea-amenorrhea syndrome: follow-up of forty-five patients after pituitary tumor removal. Ann Intern Med 94: 302–307, 1981

    Google Scholar 

  69. 69.

    Serri O, Rasio E, Beauregard H, Hardy J, Somma M: Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Engl J Med 309: 280–283, 1983

    Google Scholar 

  70. 70.

    Fahlbusch R, Buchfelder M: Present status of neurosurgery in the treatment of prolactinomas. Neurosurg Rev 8: 195–205, 1985

    Google Scholar 

  71. 71.

    Laws ER, Chenelle AG, Thapar K: Recurrence after transsphenoidal surgery for pituitary adenomas. In: Fahlbusch R, von Werder K (eds) Pituitary Adenomas: From Basic Research to Diagnosis and Therapy. Elsevier, Amsterdam, 1996, pp 3–9

    Google Scholar 

  72. 72.

    Rush SC, Newall J: Pituitary adenoma: the efficacy of radiotherapy as the sole treatment. Int J Radiat Oncol Biol Phys 17: 165–169, 1989

    Google Scholar 

  73. 73.

    Tsagarakis S, Grossman A, Plowman PN, Jones AE, Touzel R, Rees LH, Wass JA, Besser GM: Megavoltage pituitary irradiation in the management of prolactinomas: long-term follow-up. Clin Endocrinol (Oxf) 34: 399–406, 1991

    Google Scholar 

  74. 74.

    Grossman A, Besser M, Wass J, Rees L: Treatment of prolactinomas with megavoltage radiotherapy. Br Med J (Clin Res Ed) 288: 2002–1984

  75. 75.

    Landolt AM, Lomax N: Gamma knife radiosurgery for prolactinomas. J Neurosurg 93(3): 14–18, 2000

    Google Scholar 

  76. 76.

    Molitch ME: Pregnancy and the hyperprolactinemicwoman. N Engl J Med 312: 1364–1370, 1985

    Google Scholar 

  77. 77.

    Krupp P, Monka C: Bromocriptine in pregnancy: safety aspects. Klin Wochenschr 65: 823–827, 1987

    Google Scholar 

Download references

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Nomikos, P., Buchfelder, M. & Fahlbusch, R. Current management of prolactinomas. J Neurooncol 54, 139–150 (2001). https://doi.org/10.1023/A:1012905415868

Download citation

  • prolactinoma
  • pituitary adenoma
  • medical treatment
  • surgical management